Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Rese-cel (formerly CABA-201) in Pemphigus Vulgaris. The expected timing is based on the latest available company guidance and may change.
06/03/26:- PC-free PV program update: higher-dose cohorts enrolling. PC-free dose-ranging data planned; longer-term data remains expected H2 2026. 08/13/26:- RESET-PV PC-free data were presented at ASGCT 2026. Higher-dose cohorts are enrolling; longer-term data is expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.